Recruitment

Recruitment Status
Terminated

Inclusion Criteria

A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
Able to perform technical satisfactory pulmonary function test
Affiliation to the French social security system or beneficiary of such a system
...
A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
Able to perform technical satisfactory pulmonary function test
Affiliation to the French social security system or beneficiary of such a system
Having signed an informed consent from prior to participation in the trial
A smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year
Able to be trained in the proper use of a MDI
Male or female patients 40 years of age or older

Exclusion Criteria

Known narrow-angle glaucoma
Patient in emergency situations
Patient deprived of their freedom by a judicial or administrative decision
...
Known narrow-angle glaucoma
Patient in emergency situations
Patient deprived of their freedom by a judicial or administrative decision
Use of cromolyn sodium or nedocromil sodium
History of or active alcohol or drug abuse
History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
Significant disease other than COPD. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
Known active tuberculosis
History of cancer, other than treated basal cell carcinoma, within the last five years
Recent history (i.e., three years or less) of heart failure or any cardiac arrhythmia requiring drug therapy
Previous participation in this study
Patient leaving in medical or social establishments
Serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80IU/L, bilirubin >2.0mg/dL or creatinine >2.0mg/dL
Use of an investigational drug within one month or six half lives prior to the screening visit
Current significant psychiatric disorders
Use of oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose before screening visit or a change between the screening visit and visit2) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20mg every other day
Patient hospitalized for mental disorder without his (her) consent
Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
Changes in the therapeutic plan within the last six weeks prior to the screening visit or between the screening visit and visit 2, excluding changes from long acting or oral beta-adrenergics to short acting inhaled beta-adrenergics for purposes of this trial
Regular use of daytime oxygen therapy
History of thoracotomy with pulmonary resection. History or a thoracotomy for other reasons should be evaluated as per exclusion criteria no. 1
Use of antihistamines.
Serum potassium level above or below the normal range
Upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit or between the screening visit and visit 2
Clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
Use of oral beta-adrenergics or long-acting beta-adrenergics such as salmeterol (Serevent®) and formoterol in the two weeks prior to the screening visit or between the screening visit and visit 2
Recent history (i.e., one year or less) of myocardial infarction
Known symptomatic prostatic hypertrophy or bladder neck obstruction
History of asthma, allergic rhinitis or atopy
Patient under guardianship
Use of beta-blocker medications, mono-amine oxidase inhibitors or tricyclic antidepressants
Total blood eosinophil count >=600/mm³
Known hypersensitivity to anti-cholinergic or beta-agonist drugs or any other component of either Combivent® formulations

Summary

Conditions
Pulmonary Disease, Chronic Obstructive
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: Double
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 40 years and 125 years
Gender
Both males and females

Inclusion Criteria

A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
Able to perform technical satisfactory pulmonary function test
Affiliation to the French social security system or beneficiary of such a system
...
A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
Able to perform technical satisfactory pulmonary function test
Affiliation to the French social security system or beneficiary of such a system
Having signed an informed consent from prior to participation in the trial
A smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year
Able to be trained in the proper use of a MDI
Male or female patients 40 years of age or older

Exclusion Criteria

Known narrow-angle glaucoma
Patient in emergency situations
Patient deprived of their freedom by a judicial or administrative decision
...
Known narrow-angle glaucoma
Patient in emergency situations
Patient deprived of their freedom by a judicial or administrative decision
Use of cromolyn sodium or nedocromil sodium
History of or active alcohol or drug abuse
History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
Significant disease other than COPD. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
Known active tuberculosis
History of cancer, other than treated basal cell carcinoma, within the last five years
Recent history (i.e., three years or less) of heart failure or any cardiac arrhythmia requiring drug therapy
Previous participation in this study
Patient leaving in medical or social establishments
Serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80IU/L, bilirubin >2.0mg/dL or creatinine >2.0mg/dL
Use of an investigational drug within one month or six half lives prior to the screening visit
Current significant psychiatric disorders
Use of oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose before screening visit or a change between the screening visit and visit2) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20mg every other day
Patient hospitalized for mental disorder without his (her) consent
Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
Changes in the therapeutic plan within the last six weeks prior to the screening visit or between the screening visit and visit 2, excluding changes from long acting or oral beta-adrenergics to short acting inhaled beta-adrenergics for purposes of this trial
Regular use of daytime oxygen therapy
History of thoracotomy with pulmonary resection. History or a thoracotomy for other reasons should be evaluated as per exclusion criteria no. 1
Use of antihistamines.
Serum potassium level above or below the normal range
Upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit or between the screening visit and visit 2
Clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
Use of oral beta-adrenergics or long-acting beta-adrenergics such as salmeterol (Serevent®) and formoterol in the two weeks prior to the screening visit or between the screening visit and visit 2
Recent history (i.e., one year or less) of myocardial infarction
Known symptomatic prostatic hypertrophy or bladder neck obstruction
History of asthma, allergic rhinitis or atopy
Patient under guardianship
Use of beta-blocker medications, mono-amine oxidase inhibitors or tricyclic antidepressants
Total blood eosinophil count >=600/mm³
Known hypersensitivity to anti-cholinergic or beta-agonist drugs or any other component of either Combivent® formulations

Tracking Information

NCT #
NCT02182869
Collaborators
Not Provided
Investigators
Not Provided